Premium
Immunotherapy of Melanoma: Current Status and Prospects for the Future
Author(s) -
Irie Reiko F.,
DeNunzio F. David
Publication year - 1993
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1993.tb03833.x
Subject(s) - immunotherapy , melanoma , monoclonal antibody , lymphokine , immunology , cancer immunotherapy , medicine , antigen , active immunotherapy , cytotoxic t cell , immune system , cancer research , antibody , biology , in vitro , biochemistry
Abstract As one of the most immunogenic human malignancies, melanoma has served as a prototype for the development of immunotherapy against human cancer in a number of treatment modalities over the past two decades. These studies have included augmentation of host immunity with lymphokines and other biological response modifiers, lymphokine‐activated killer cells, and cytotoxic T‐cells; active immunotherapy using purified antigens, tumor cell vaccines, and anti‐id antibodies; and passive immunotherapy with monoclonal antibodies. The results of these investigations are discussed as well as the prospect for future treatments of melanoma incorporating immunotherapeutic techniques. A report on a recent trial of gene therapy of human melanoma performed by Dr. Steven Rosenberg is also presented.